

NOVO NORDISK

Prize Diabetology

2017-2018

Call for entry

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen and on the New York Stock Exchange as American Depositary Receipts (ADRs). For more information, visit novonordisk.com.

The Novo Nordisk prize for Diabetology wants to encourage Diabetes research

Submission Process:

Registration takes place through an email sent to dvra@novonordisk.com including coordinates of the candidate and project title. The deadline for submitting the final thesis is December 31, 2017, and the prize will be awarded during the last quarter of 2018.

Eligibility:

The candidate must hold a medical degree, be younger than 45 in December 2017 and has to be attached to a Belgian or Luxembourg institution.